Hematopoiesis is a well-orchestrated process through which the most primitive cells of the hematopoietic system, i.e., hematopoietic stem cells (HSCs), differentiate into mature cells of the myeloid-erythroid and lymphoid lineages ([@bib25]; [@bib27]; [@bib28]). HSCs are rare and reside in specialized niches located within the BM. In the absence of specific mitogenic stimuli, HSCs remain in a quiescent or dormant state ([@bib43]). However, under stress conditions, such as bleeding, myeloablation, total body irradiation, and infection, HSCs can enter into an active proliferative state ([@bib30]). Although HSCs are controlled mainly by intrinsic pathways, often HSCs need and respond to external stimuli such as cytokines, chemokines, and cell--cell contacts. Whenever HSCs divide into daughter cells, the fates of the daughter cells, including life versus death and self-renewal versus differentiation, need to be tightly regulated because defects in these cell fate decisions will have detrimental consequences, including BM failure and hematologic malignancies ([@bib30]).

Self-renewal and differentiation of HSCs are complex processes and are dependent on the immediate "turning on" or "turning off" of various cytokine receptors, signal transducers, transcription factors, and cell cycle inhibitors. Although transcriptional regulation of gene expression and the involvement of transcription factors in hematopoiesis have been studied to a greater extent, the role of posttranslational modifications (PTMs) of proteins, in particular ubiquitination, in the regulation of hematopoiesis remains largely unknown. Recent studies, including our own, have highlighted the importance of the ubiquitin proteasome system in the development and functions of normal HSCs and leukemic stem cells ([@bib34], [@bib35], [@bib36]; [@bib33]; [@bib24]). Even though these studies have provided clues regarding the physiological relevance of PTMs in hematopoiesis, a clearer understanding of the significance of PTMs mediated by the ubiquitin proteasome system in early hematopoiesis remains elusive. Moreover, these studies were based on the functions of E3 ubiquitin ligases, such as c-Cbl, Itch, and Fbxw7, and the role of deubiquitinases (DUBs) in early hematopoiesis and in stem cell biology needs to be explored.

A20 (also known as Tnfaip3 and referred as A20 henceforth) is a potent antiinflammatory signaling molecule that restricts multiple intracellular signaling cascades ([@bib21]). A20 is an ∼90-kD protein that belongs to the ovarian tumor (OTU) family of DUBs. A unique feature of A20 is that it contains an N-terminal cysteine protease/DUB domain (which is necessary for the deubiquitylating functions) and a C-terminal zinc finger (ZNF) domain (which confers the E3 ubiquitin ligase functions). Thus, A20 can be classified as a dual-function ubiquitin-editing enzyme ([@bib46]). A20 catalyzes the K48-linked ubiquitylation of target proteins through its C-terminal ZNF domain, an action which directs the target proteins for proteasomal degradation. Concurrently, A20 removes K63-linked ubiquitin chains from its target proteins (through its DUB activity), which not only inactivates the signaling function of the targets, but might also facilitate its K48-linked ubiquitylation and degradation ([@bib46]). The negative signaling function of A20 involves deconjugation of K63-linked ubiquitin chains from TRAF6 and RIP1, which are central players of the TLR and TNF receptor (TNFR) pathways ([@bib41]). In addition, A20 also mediates deubiquitylation of RIP2 and therefore acts as a negative regulator of NF-κB signaling ([@bib12]; [@bib41]; [@bib44]; [@bib14]).

In view of the fact that A20 has a key role in the control of inflammation and that inflammatory signals can impact HSC development and functions, we hypothesized that A20 functions as a critical regulator of the HSC pool. To validate this, we generated and investigated mice that lack A20 expression in HSCs (and in their progeny). Deficiency of A20 in the hematopoietic system resulted in reduced body size and weight and postnatal lethality. BM and thymic cellularity was remarkably reduced, whereas extramedullary hematopoiesis in the spleen and liver was increased in A20 mutant mice. Loss of A20 led to a striking reduction of the long-term HSC (LT-HSC) pool and an increase of the short-term HSC (ST-HSC) pool. A20-deficient HSCs exhibited compromised abilities to provide radioprotection and hematopoietic reconstitution in lethally irradiated WT recipients. Hematopoietic stem and progenitor cells (HSPCs) of A20 mutant mice showed hyperproliferation, loss of quiescence, and reduced expression of p57. Our mechanistic experiments in A20-deficient mice identified augmented IFN-γ signaling in HSCs and elevated IFN-γ expression by hematopoietic cells, as the result of increased NF-κB binding to the promoter of *Ifn-**γ***. Notably, loss of IFN-γ in A20-deficient mice partially rescued the HSC phenotype. Overall, our experiments identified the importance of A20-mediated suppression of inflammatory signals in HSC homeostasis and highlighted ubiquitin editing as a novel mechanism in the control of HSC quiescence.

RESULTS
=======

A20 deficiency in HSCs causes postnatal lethality
-------------------------------------------------

To identify whether A20 is expressed during early hematopoiesis, we divided BM Lineage^−^Sca1^+^c-Kit^+^ (LSK) cells from C57BL/6 WT mice into LT-HSCs (CD150^+^CD48^−^LSK), ST-HSCs (CD34^+^Flt3^−^LSK), and multipotent progenitors (MPPs; CD34^+^Flt3^+^LSK), sorted them individually, and quantified expression levels of *A20* mRNA by RT-PCR. Indeed, *A20* was expressed in all three LSK subsets (i.e., LT-HSCs, ST-HSCs, and MPPs), in c-Kit^+^Lin^−^ myeloid progenitor cells, and in total BM cells ([Fig. 1 A](#fig1){ref-type="fig"}). Of note, the highest expression levels of *A20* were found in ST-HSCs ([Fig. 1 B](#fig1){ref-type="fig"}). To study the functions of A20 in HSCs, we generated mice with *lox*P-flanked alleles of the gene encoding mouse *A20* ([Fig. 1 C](#fig1){ref-type="fig"}). To analyze Cre-mediated ablation of A20 expression, we crossed A20 Floxed mice with the ubiquitous-Cγ1-Cre animals to obtain A20^Flox/Flox^ Cγ1-Cre (designated as *A20^−/−^*) mice. To test whether A20 is deleted in these mice, mesenchymal embryonic fibroblasts (MEFs) were generated, from either control or *A20^−/−^* embryos, and stimulated with TNF (as it induces A20 expression in MEFs). Western blot analysis indicated the presence and induction of A20 protein in control MEFs, but it was completely abolished in A20^−/−^ MEFs (not depicted). We also used antibodies that recognize the N-terminal epitope of A20, which may still present in the truncated A20 protein, and confirmed that no aberrant A20 protein was expressed in these cells (not depicted). To delete A20 in HSCs, we crossed A20^F/F^ mice with the Vav-Cre transgenic mice ([@bib26]) to generate A20^Flox/Flox^Vav^Cre/+^ (called A20^Hem-KO^ here) mice and confirmed that A20 protein was predominantly absent in the hematopoietic organs, such as BM, spleen, and thymus. As expected, A20 expression was intact in nonhematopoietic organs, such as brain, kidney, and heart ([Fig. 1 D](#fig1){ref-type="fig"}).

![**A20 deficiency leads to pathological hematopoiesis.** (A and B) Reverse transcription--PCR (A) and real-time PCR (B) analyses showing *A20* mRNA expression in the indicated hematopoietic subsets of WT BM. Expression levels of *A20* were normalized to *Hprt* levels. (C) Scheme representing the *Tnfaip3* gene targeting strategy. (D) Western blot analysis of A20 protein in cells from the indicated organs of A20^Hem-KO^ and WT control mice. (E) Representative images of control and A20^Hem-KO^ mice showing body size. (F) Total body weight of control (*n* = 4) and A20^Hem-KO^ (*n* = 5) mice at 14 d of birth. (G) Kaplan-Meier survival curve analysis of A20^Hem-KO^ (*n* = 15) and control (*n* = 15) mice. Significance (\*\*\*, P \< 0.001) was assessed using the log-rank test. (H) Representative images of thymus, spleen, and liver of 14-d-old A20^Hem-KO^ and control mice. (I) Cellularity of BM (two femurs and two tibias), thymus, and spleen of 14-d-old A20^Hem-KO^ (*n* = 13--14) and control (*n* = 13--14) mice. Data are representative of 10 independent experiments. (J) Representative hematoxylin and eosin images (bars, 0.5 mm) of spleen and liver of 14-d-old A20^Hem-KO^ and control mice. In each panel, a high-magnification image is shown at the top left corner. (A, B, D, and J) Data are representative of two independent experiments. (K) FACS plots of LSK and Lin^−^c-Kit^+^Sca1^−^ cells in the spleen and liver of 14-d-old A20^Hem-KO^ and control mice. Data are representative of three independent experiments. (L) Differential blood count analysis of 14-d-old A20^Hem-KO^ (*n* = 7) and control (*n* = 7) mice. Data are pooled from seven independent experiments. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001).](JEM_20132544_Fig1){#fig1}

A20^Hem-KO^ mice were born at Mendelian ratios; however, they exhibited ∼50% reduction of body size and weight ([Fig. 1, E and F](#fig1){ref-type="fig"}), as compared with their littermate controls. Strikingly, almost all A20^Hem-KO^ mice died before their weaning age (∼21 d) and had a median lifespan of 14 d ([Fig. 1 G](#fig1){ref-type="fig"}). Analysis of 14-d-old A20^Hem-KO^ mice indicated ([Fig. 1 H](#fig1){ref-type="fig"}) thymic atrophy (reduced thymus), splenomegaly (increased spleen size), and hepatomegaly (enlarged liver). Cell count analysis showed an ∼50% reduction in BM cellularity, ∼90% reduction in thymic cellularity, and ∼400% increase in splenic cellularity of A20^Hem-KO^ mice ([Fig. 1 I](#fig1){ref-type="fig"}). Histopathological analysis of spleen and liver of A20^Hem-KO^ mice revealed disrupted architecture, infiltration of leukocytes ([Fig. 1 J](#fig1){ref-type="fig"}), and extramedullary hematopoiesis ([Fig. 1 K](#fig1){ref-type="fig"}). Peripheral blood count analysis of A20^Hem-KO^ mice indicated elevated WBC counts and reduced hemoglobin and platelets counts ([Fig. 1 L](#fig1){ref-type="fig"}). Collectively, these data suggest that A20 has an indispensable role in restricting pathological hematopoiesis.

A20 controls the HSC pool
-------------------------

To determine whether the HSC pool of A20^Hem-KO^ mice was altered, we performed immunophenotyping experiments of HSCs and HSPCs by flow cytometry. Analysis of the LSK compartment, consisting of LT-HSCs, ST-HSCs, and MPPs, revealed a remarkable increase (3.2% in control and 17.9% in KO) of relative numbers in the BM of A20^Hem-KO^ mice ([Fig. 2 A](#fig2){ref-type="fig"}). Further investigation of LSK cells indicated a striking reduction of LT-HSCs (4.8% in control and 0.09% in KO) and MPPs (64% in control and 8% in KO) in the BM of A20^Hem-KO^ mice ([Fig. 2 A](#fig2){ref-type="fig"}). Interestingly, frequencies of ST-HSCs were increased (27% in control and 86% in KO) in the BM A20^Hem-KO^ mice ([Fig. 2 A](#fig2){ref-type="fig"}). Next, we enumerated the absolute numbers of HSPC subsets of the BM. Even though the relative frequencies of LSK cells were increased in A20^Hem-KO^ mice, the absolute numbers of LSK cells were comparable between controls and A20^Hem-KO^ mice ([Fig. 2 B](#fig2){ref-type="fig"}). Consistent with their relative numbers, the absolute numbers of LT-HSCs and MPPs were decreased, and the absolute numbers of ST-HSCs were increased in the BM of A20^Hem-KO^ mice ([Fig. 2 B](#fig2){ref-type="fig"}).

![**The HSPC pool is attenuated in A20-deficient mice.** (A) FACS plots of LSK cells, LT-HSCs, ST-HSCs, and MPPs from the BM (two femurs and two tibias) of 14-d-old A20^Hem-KO^ and control mice. Data are representative of 10 independent experiments. (B) Absolute numbers of LSK cells, LT-HSCs, ST-HSCs, and MPPs from the BM (two femurs and two tibias) of 14-d-old A20^Hem-KO^ (*n* = 5) and control (*n* = 5) mice. (C) FACS plots of SP cells in the BM of 14-d-old A20^Hem-KO^ and control mice. Data are representative of three independent experiments. (D) Relative frequencies of SP cells in the BM of 14-d-old A20^Hem-KO^ (*n* = 3) and control (*n* = 3) mice. Data are pooled from three independent experiments. (E) FACS plots of quiescent HSCs and MPP subsets in the BM of 14-d-old A20^Hem-KO^ (*n* = 4) and control (*n* = 4) mice. Data are representative of eight independent experiments. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*\*, P \< 0.001).](JEM_20132544_Fig2){#fig2}

To independently confirm these findings through an alternative technique, we performed "side population" (SP) analysis ([@bib10]). This technique utilizes the fluorescent DNA-binding dye Hoechst 33342 to identify and purify mouse HSCs in the BM, as only HSCs, but not differentiated hematopoietic cells, will have the abilities to pump out the Hoechst 33342 dye. Our SP analysis identified a remarkable decrease (0.047% in control and 0.015% in KO) of SP cells in the BM of A20^Hem-KO^ mice ([Fig. 2, C and D](#fig2){ref-type="fig"}).

To further strengthen these data, we adopted the immunophenotyping strategy, developed by the Trumpp laboratory ([@bib47]), that distinguishes HSPCs of the mouse BM into five distinct stages: HSC (LSK CD150^+^CD48^−^CD34^−^Flt3^−^), MPP1 (LSK CD150^+^CD48^−^CD34^+^Flt3^−^), MPP2 (LSK CD150^+^CD48^+^CD34^+^Flt3^−^), MPP3 (LSK CD150^−^CD48^+^CD34^+^Flt3^−^), and MPP4 (LSK CD150^−^CD48^+^CD34^+^Flt3^+^). According to this study ([@bib47]), the most primitive HSC (LSK CD150^+^CD48^−^CD34^−^Flt3^−^) fraction remains largely quiescent, and the transition from MPP1 to MPP4 stage is accompanied by a gradual loss of quiescence and an increase of proliferation. As expected, we detected almost no HSCs (13% in control and 0% in KO), slightly increased MPP1 (82% in control and 100% in KO), modestly reduced MPP2 (92% in control and 63% in KO), remarkably increased MMP3 (26% in control and 89% in KO), and highly reduced MPP4 (66% in control and 6% in KO) in the BM of A20^Hem-KO^ mice ([Fig. 2 E](#fig2){ref-type="fig"}). These data suggested that the more quiescent HSC fraction was completely depleted and the transition from MPP3 to MPP4 was severely affected in the absence of A20-mediated functions in HSCs. Overall, the immunophenotyping experiments demonstrated that the HSC pool is remarkably reduced in the BM of A20^Hem-KO^ mice.

A20-deficient HSCs have compromised functions
---------------------------------------------

To assess the functions of A20 mutant HSCs, we performed BM transplantation (BMT) experiments. Transfer of A20-deficient BM cells (10^6^) into lethally (10 Gy) irradiated WT animals failed to provide radioprotection in ∼70% of the recipients ([Fig. 3 A](#fig3){ref-type="fig"}). Even though the remaining ∼30% of recipients (which received A20-deficient BM) survived for \>3 wk, they developed severe leukopenia, anemia, and thrombocytopenia, starting at 2 wk after transplantation ([Fig. 3 B](#fig3){ref-type="fig"}). In these survivors, A20 mutant--derived chimerism was \>95% at 2 wk after transplantation, but it was dropped to ∼10% at 4 wk after transplantation ([Fig. 3, C and D](#fig3){ref-type="fig"}). Transfer of BM from the survivors that showed a donor chimera of ∼10% into lethally irradiated WT secondary recipients failed to provide detectable levels (\<1%) of donor chimerism at 4 wk after transplantation ([Fig. 3 E](#fig3){ref-type="fig"}). We repeated these experiments using purified LSK cells and obtained similar results (not depicted). Based on the fact that we detected A20 mutant--derived hematopoiesis at 2 wk after transplantation, we reasoned that homing defects might not be responsible for the reduced engraftment in recipients. To substantiate this, we performed homing experiments using CFSE-labeled LSK cells and found that the homing capacities were comparable between control and A20^Hem-KO^ HSPCs ([Fig. 3 F](#fig3){ref-type="fig"}).

![**Loss of A20 causes impaired HSC functions.** (A) Kaplan-Meier survival curve analysis of WT recipients (CD45.1^+^) that received BM of either A20^Hem-KO^ or control mice (CD45.2^+^) after lethal (10 Gy) irradiation. Each group represents data from a pool of 13 animals. Significance (\*\*, P \< 0.004) was assessed using the log-rank test. (B) Differential blood count analysis of WT congenic (CD45.1^+^) recipients that received BM cells from either A20^Hem-KO^ or WT mice, at 2 wk after transplantation. Data are pooled from three mice per group. (C) FACS plots of donor (either WT or A20^Hem-KO^)-derived chimera (CD45.2^+^) in the peripheral blood of WT congenic (CD45.1^+^) recipients, at 2 wk after transplantation. (D) Frequencies of donor (CD45.2^+^)-derived hematopoiesis, at 4 wk after transplantation, in the peripheral blood of WT (CD45.1^+^) recipients that survived lethal irradiation (survivors of A). Data are pooled from five mice in the control group and four mice in the A20^Hem-KO^ group. (E) Serial transplantation experiments: Frequencies of donor (CD45.2^+^) cells in the peripheral blood of secondary WT recipients, at 4 wk after transplantation. Data are pooled from five mice per group. (F) FACS plots indicating frequencies of CFSE^+^ cells in the BM of lethally irradiated WT recipients that received CFSE-labeled LSK cells of either A20^Hem-KO^ or WT control mice at 20 h after injection. Data are representative of two independent experiments with four mice per group. (G and H) Frequencies of donor (CD45.2^+^) hematopoiesis in the peripheral blood (G) and BM, spleen, and thymus (H) of WT recipients, at 4 wk after transplantation. Recipients received mixed chimera containing donor (CD45.2^+^) BM cells (from either A20^Hem-KO^ or control mice) and WT competitor (CD45.1^+^) BM cells at a ratio of 1:1 (G) and 3:1 (G and H), respectively. Data are representative of two independent experiments with four mice per group (G) and four mice for WT and five mice for A20^Hem-KO^ groups (H). (I and J) Frequencies of donor (CD45.2^+^)-derived cells in total CD11b^+^ (I) and CD19^+^ (J) fractions of the peripheral blood from WT recipients, at 4 wk after transplantation. Recipients received mixed chimera containing donor (CD45.2^+^) BM cells (from either A20^Hem-KO^ or control mice) and WT competitor (CD45.1^+^) BM cells at a ratio of 1:1 and 3:1, respectively. Data are representative of two independent experiments with four mice per group. (K) Frequencies of donor (CD45.2^+^)-derived cells in the BM, spleen, thymus, and peripheral blood of WT recipients, at 2 and 9 wk after transplantation. Recipients received mixed chimera containing donor (CD45.2^+^) BM cells (from either A20^Hem-KO^ or control mice) and WT competitor (CD45.1^+^) BM cells at a ratio of 5:1, respectively. (L) Frequencies of donor (CD45.2^+^)-derived cells in total CD11b^+^ and CD19^+^ fractions of the peripheral blood from WT recipients, at 2 and 9 wk after transplantation. Recipients received mixed chimera containing donor (CD45.2^+^) BM cells (from either A20^Hem-KO^ or control mice) and WT competitor (CD45.1^+^) BM cells at a ratio of 5:1, respectively. (K and L) Data are representative of two independent experiments with three mice per group. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001).](JEM_20132544_Fig3){#fig3}

Next, we tested the potential of A20-deficient BM to repopulate the hematopoietic system under competitive conditions. A20-deficient and control BM cells (CD45.2^+^) were mixed with congenic (CD45.1^+^) WT BM cells at a ratio of either 1:1 or 3:1 (donor/competitor) and were injected into lethally irradiated congenic (CD45.1^+^) recipients. Analysis of donor-derived chimera at 4 wk after transplantation indicated a significant reduction of donor-derived (CD45.2^+^) hematopoiesis ([Fig. 3, G and H](#fig3){ref-type="fig"}), as well as multilineage differentiation ([Fig. 3, I and J](#fig3){ref-type="fig"}), in recipients that received A20 mutant BM. Because no detectable levels of A20 mutant--derived chimerism were seen in recipients at 4 wk after transplantation, we increased the donor/competitor ratio to 5:1 and injected into lethally irradiated WT recipients. Analysis of donor-derived chimera indicated that even though A20 mutant--derived hematopoiesis was detectable (albeit ∼50% lower than that of the control group) in recipients at 2 wk after transplantation, it was undetectable in the BM, spleen, thymus, and peripheral blood at 9 wk after transplantation ([Fig. 3, K and L](#fig3){ref-type="fig"}). Collectively, these data indicate that A20 deficiency impairs HSC functions.

A20 regulates HSC quiescence
----------------------------

Our analysis of A20^Hem-KO^ mice indicated a striking reduction of LT-HSCs in the BM ([Fig. 2 A](#fig2){ref-type="fig"}). Loss of LT-HSCs in A20 mutant BM could be explained by either increased apoptosis of LT-HSCs or increased proliferation in conjunction with decreased self-renewal of LT-HSCs. To identify the reason or reasons for the loss of the LT-HSC pool in A20 mutant mice, we first performed apoptosis experiments using Annexin V and 7-AAD. Data of these experiments indicated comparable frequencies of apoptosis between control and A20^Hem-KO^ mice (not depicted). These data were further validated using TUNEL assays, and we obtained consistent results (not depicted). Next, we performed proliferation experiments using BrdU ([@bib13]). Data of these experiments indicated that the frequencies of BrdU^+^ cells and that the intensities of incorporated BrdU were augmented both in total LSK and in CD150^+^LSK cells from 14-d-old A20^Hem-KO^ mice ([Fig. 4, A and B](#fig4){ref-type="fig"}). Because LT-HSCs were almost absent in 14-d-old A20^Hem-KO^ mice, we repeated BrdU assays with 2-d-old (P2) pups and observed that A20 mutant CD48^−^CD150^+^LSK cells proliferated more rapidly than control cells ([Fig. 4 C](#fig4){ref-type="fig"}). Consistent with this, Ki-67 expression levels were also increased in A20 mutant LSK and CD150^+^LSK cells ([Fig. 4, D and E](#fig4){ref-type="fig"}). Next, we measured HSC quiescence using Hoechst and Ki-67. As expected, the frequencies of LSK, CD150^+^LSK, and LT-HSC fractions at G0 phase were reduced in the BM of A20^Hem-KO^ mice ([Fig. 4 F](#fig4){ref-type="fig"}). Finally, we performed Pyronin Y staining to distinguish quiescent HSPCs from proliferating HSPCs ([@bib5]). Pyronin Y analysis of A20 mutant BM revealed a striking reduction (40% in control and 3.5% in KO) of LSK cells in the G0 (Pyronin Y^−^Hoechst^−^) phase of the cell cycle ([Fig. 4, G and H](#fig4){ref-type="fig"}). Collectively, these data indicated that A20 deficiency might cause loss of HSC quiescence and premature depletion of the HSC pool.

![**Deficiency of A20 results in impaired HSC quiescence.** (A and B) Representative FACS plots (A) and bar graphs (B) indicating frequencies of BrdU^+^ cells in LSK and CD150^+^LSK fractions in the BM of 14-d-old A20^Hem-KO^ and control mice, after 16-h pulse with BrdU. (A) In each histogram, the median fluorescence intensities (left) and percentages of cells under the gate (right) are indicated. Data are representative of two independent experiments with three mice per group. (C) FACS plots indicating frequencies of BrdU^+^ LT-HSCs from the livers of P2 pups after 16-h pulse with BrdU. Data are representative of two independent experiments with two pups per group. (D and E) Representative FACS plots (D) and cumulative frequencies (E) of Ki-67^+^LSK and CD150^+^LSK cells from 14-d-old A20^Hem-KO^ and control mice. (F) FACS plots indicating frequencies of HSPCs in G0 (Ki-67^−^ and Hoechst^−^), G1 (Ki-67^+^ and Hoechst^−^), and G2/S (Ki-67^+^ and Hoechst^+^) phase of cell cycle in the BM of 14-d-old A20^Hem-KO^ and control mice. (G) Representative FACS plots indicating frequencies of HSPCs in G0 (Pyronin Y^−^ and Hoechst^−^), G1 (Pyronin Y^+^ and Hoechst^−^), and G2/S (Pyronin Y^+^ and Hoechst^+^) phases of cell cycle in the BM of 14-d-old A20^Hem-KO^ and control mice. (H) Bar graph showing the frequencies of HSPCs in the G0 (Pyronin Y^−^ and Hoechst^−^) phase of the cell cycle in the BM of 14-d-old A20^Hem-KO^ and control mice. (D, E, G, and H) Data are representative of two independent experiments with two mice per group. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*\*, P \< 0.001).](JEM_20132544_Fig4){#fig4}

A20-deficient hematopoietic cells show increased NF-κB signaling
----------------------------------------------------------------

A20 is a key negative regulator of NF-κB signaling, and loss of A20 results in augmented NF-κB signal transduction ([@bib44]; [@bib14]; [@bib21]). To test whether NF-κB signaling was increased in A20^Hem-KO^ mice, we measured IκBα expression and activation. Hematopoietic cells from control and A20 mutant mice were stimulated in vitro with LPS and assessed for protein expression. Western blot data indicated a baseline reduction of total IκBα protein in unstimulated cells of A20 mutant mice. However, in response to LPS, total IκBα levels were strikingly reduced and phospho- IκBα protein levels were increased in the hematopoietic cells of A20 mutant mice ([Fig. 5, A and B](#fig5){ref-type="fig"}). Decrease of total IκBα levels and increase of phospho-IκBα suggested that NF-κB signaling was elevated in A20-deficient cells. Consistent with increased NF-κB signaling, expression levels of several NF-κB targets, such as *Relb*, *NF-κB2*, *TNF*, *BclX*, *Hif1**α***, and *Sfpi1*, were elevated in the hematopoietic cells of A20^Hem-KO^ mice ([Fig. 5 C](#fig5){ref-type="fig"}). These data support the previous findings ([@bib44]; [@bib14]; [@bib21]) that NF-κB signaling is augmented in A20-deficient hematopoietic cells.

![**Augmented NF-κB activation in A20-deficient hematopoietic cells.** (A) Western blot analysis of total and phospho- IκBα in splenocytes either in the presence or absence of LPS stimulation for 1 h. Data are representative of two independent experiments. (B) Quantification of proteins from Western blot shown in A. IκBα protein levels were normalized to Actin protein levels in each lane, respectively. Data are pooled from two independent experiments. (C) Real-time PCR data indicating expression levels of NF-κB target genes in the total BM cells of 14-d-old A20^Hem-KO^ and control mice. Expression levels of target genes were normalized to HPRT levels. Data are representative of three independent experiments. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05).](JEM_20132544_Fig5){#fig5}

Increased IFN-γ signaling in A20 mutant HSCs
--------------------------------------------

Earlier studies identified IFN-γ as a direct target of NF-κB proteins ([@bib39]), and based on the critical role of IFN-γ in the maintenance of HSCs ([@bib2]; [@bib15]), we hypothesized that deregulated IFN-γ signaling might be potentially responsible for the HSC phenotype of A20^Hem-KO^ mice. To test this, we measured the expression levels of IFN-γ in A20^Hem-KO^ mice. In line with our hypothesis, we detected elevated levels of *Ifn-**γ*** mRNA in both BM and spleen of A20-deficient mice ([Fig. 6 A](#fig6){ref-type="fig"}). To substantiate this finding and to identify the cellular source of IFN-γ in A20 mutant mice, we crossed A20^Hem-KO^ mice with the IFN-γ--YFP reporter GREAT (IFN-γ reporter with endogenous polyA transcript) mice ([@bib37]). These transgenic mice have an IRES-eYFP reporter cassette inserted between the translational stop codon and the 3′ UTR/polyA tail of the *Ifn-**γ*** gene ([@bib37]). Our analysis of hematopoietic compartments from GREAT-A20^Hem-KO^ mice suggested an elevated expression of YFP and, therefore, IFN-γ in CD11C^+^, CD3^+^CD4^+^, and CD3^+^CD8^+^ cells of BM and spleen ([Fig. 6 B](#fig6){ref-type="fig"}). In addition, myeloid cells, such as granulocytes and monocytes, from GREAT-A20^Hem-KO^ mice also expressed YFP, albeit at lower levels ([Fig. 6 B](#fig6){ref-type="fig"}). Next, we tested whether *Ifn-**γ*** is a direct target of NF-κB in A20 mutant BM cells. Our analysis of mouse *Ifn-**γ*** gene sequences indicated the presence of five (AAGGACTTCCTC) NF-κB--binding sites ([@bib48]) in its promoter region. Among these sites, one NF-κB--binding site (from −541 to −530) is highly conserved across species ([Fig. 6, C and D](#fig6){ref-type="fig"}), and chromatin immunoprecipitation (ChIP) data revealed an increased binding of NF-κB to the *Ifn-**γ*** promoter in A20^Hem-KO^ BM cells ([Fig. 6 E](#fig6){ref-type="fig"}). To understand the physiological relevance of deregulated IFN-γ expression on the HSC compartment, we investigated whether IFN-γ signaling was augmented in the HSCs from A20^Hem-KO^ mice. Real-time PCR data indicated that the expression levels of IFN-γ target genes, such as *Irf1*, *Irgm1*, and *STAT1*, were elevated in A20 mutant HSCs ([Fig. 6 F](#fig6){ref-type="fig"}). Deregulated IFN-γ signaling results in up-regulated surface expression of Sca1 in HSPCs, as Sca1 is a direct target of IFN-γ ([@bib40]; [@bib15]). Our analysis of the LSK compartment indicated increased surface expression of Sca1 in hematopoietic progenitors and in total BM cells of A20^Hem-KO^ mice ([Fig. 6, G and H](#fig6){ref-type="fig"}; and not depicted). Intriguingly, up-regulation of Sca1 in HSPCs has been connected with increased cell cycle activity ([@bib9]).

![**Increased IFN-γ signaling in A20-deficient HSCs.** (A) Real-time PCR data indicating expression levels of *Ifn-γ* transcripts in the BM cells and splenocytes of 14-d-old A20^Hem-KO^ and control mice. Expression levels of *Ifn-γ* were normalized to *Hprt* levels. (B) FACS plots indicating YFP expression in the BM cells and splenocytes of IFN-γ--YFP reporter (GREAT) mice, crossed with either control or A20^Hem-KO^ mice. (A and B) Data are representative of three independent experiments. (C) Diagrammatic representation of the *Ifn-γ* gene indicating the presence of five NF-κB--binding sites in its promoter. (D) NF-κB--binding site in the promoter of *Ifn-γ* gene of the indicated species. (E) ChIP analysis of NF-κB (p65) binding to the *Ifn-γ* promoter in the BM cells of 14-d-old A20^Hem-KO^ and control mice. Shown are the real-time PCR data of p65 immunoprecipitates, which were normalized to IgG control immunoprecipitates. Data are representative of two independent experiments. (F) Real-time PCR data indicating expression of IFN-γ target genes in CD150^+^LSK cells from 14-d-old A20^Hem-KO^ and control mice. Expression levels of target genes were normalized to *Hprt* levels. Data are pooled from two independent experiments with six mice per group. (G and H) Representative FACS plots (G) and cumulative frequencies (H) indicating expression levels of Sca1 in Lin^−^c-Kit^+^CD150^+^ cells of the BM from 14-d-old A20^Hem-KO^ and control mice. Data are representative of 10 independent experiments (G) and are pooled from six mice per group (H). (I) Real-time PCR data indicating expression levels of IFN-γ--controlled cell cycle regulators in HSCs of 14-d-old A20^Hem-KO^ and control mice. Expression levels of target genes were normalized to *Hprt* levels. Data are representative of two independent experiments with six mice per group. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001).](JEM_20132544_Fig6){#fig6}

At the molecular level, a major functional consequence of increased IFN-γ signaling is diminished HSC quiescence, probably caused by deregulated expression of cell cycle regulators, such as CcnD1 and p57, and other key transcriptional targets ([@bib7]). Our gene expression experiments identified an increase in the expression levels of *CcnD1* (a positive regulator of cell cycle) and a decrease in the expression levels of *p57* (a negative regulator of cell cycle) in A20-deficient CD150^+^LSK cells ([Fig. 6 I](#fig6){ref-type="fig"}). Of note, HSCs that are deficient for D-Cyclins show reduced proliferation ([@bib18]; [@bib31]), and HSCs lacking p57 failed to reconstitute the hematopoietic system because of loss of quiescence ([@bib23]), a phenotype which is very similar to the phenotype of A20-deficient HSCs. Overall, these data suggest that IFN-γ expression and signaling were elevated in A20^Hem-KO^ mice, and as a consequence, their target genes were up-regulated in HSCs of these animals.

Rescue of the HSC phenotype in A20^Hem-KO^ IFN-γ^−/−^ mice
----------------------------------------------------------

To directly address the involvement of IFN-γ signaling in the phenotype of A20^Hem-KO^ mice, we crossed A20^Hem-KO^ mice with IFN-γ^−/−^ mice to obtain A20^Hem-KO^ IFN-γ^−/−^ (double KO \[DKO\]) mice. Strikingly, DKO mice were larger in size and showed more body weight than the A20^Hem-KO^ littermates ([Fig. 7, A and B](#fig7){ref-type="fig"}). However, DKO mice were slightly smaller and lighter than the A20^F/+^ littermate controls ([Fig. 7, A and B](#fig7){ref-type="fig"}). Survival curve analysis indicated that postnatal lethality of A20^Hem-KO^ mice was rescued in the DKO mice ([Fig. 7 C](#fig7){ref-type="fig"}). Analysis of the HSPC compartment in the BM of DKO mice revealed a rescue of the LSK phenotype ([Fig. 7 D](#fig7){ref-type="fig"}). Consistently, the phenotype (relative frequencies) of LSK subsets, including LT-HSCs, ST-HSCs, and MPPs, was rescued in DKO mice ([Fig. 7 D](#fig7){ref-type="fig"}). Absolute numbers of LT-HSCs indicated a significant increase (∼300%) of LT-HSC numbers in the DKO mice when compared with their A20^Hem-KO^ littermates ([Fig. 7 E](#fig7){ref-type="fig"}). However, when compared with the littermate controls, the numbers of LT-HSCs were still reduced in the DKO mice ([Fig. 7 E](#fig7){ref-type="fig"}). In addition, surface expression of Sca1 was restored to WT levels in DKO progenitor cells ([Fig. 7 F](#fig7){ref-type="fig"}). Next, we performed BMT experiments to assess the functions of DKO HSCs. Transfer of total BM cells (CD45.2^+^) from control, IFN-γ^−/−^, A20^Hem-KO^, and DKO mice into lethally irradiated WT congenic (CD45.1^+^) recipients resulted in comparable survival among control, IFN-γ^−/−^, and DKO recipient groups, whereas mice that received A20^Hem-KO^ BM showed reduced survival ([Fig. 7 G](#fig7){ref-type="fig"}). In these particular experiments ([Fig. 7 G](#fig7){ref-type="fig"}), we did not observe compromised survival of the recipients that received A20 mutant BM to the extent shown in [Fig. 3 A](#fig3){ref-type="fig"}. Nevertheless, analysis of survivors at 5 wk after transplantation indicated undetectable levels of donor cells in recipients that received A20^Hem-KO^ BM cells ([Fig. 7 H](#fig7){ref-type="fig"}). In contrast, recipients that received DKO BM cells had ∼40% donor-derived chimera at 5 wk after transplantation ([Fig. 7 H](#fig7){ref-type="fig"}), and more importantly, remarkable levels of donor-derived chimera were maintained even at 14 wk after transplantation ([Fig. 7 I](#fig7){ref-type="fig"}). To further strengthen these findings, we performed competitive repopulation experiments (donor/competitor ratio = 5:1 and 1:1, respectively) with control, A20^Hem-KO^, and DKO BM cells. Analysis of recipients indicated detectable levels of donor-derived chimera in both control and DKO groups, whereas donor-derived hematopoiesis was completely absent in recipients that received A20^Hem-KO^ BM ([Fig. 7, J and K](#fig7){ref-type="fig"}). Nevertheless, frequencies of donor-derived hematopoiesis were lower in recipients that received DKO BM when compared with the chimera derived from littermate control BM. Donor-derived multilineage analysis indicated intact differentiation of both myeloid and lymphoid lineage cells from DKO BM, whereas it was completely absent in recipients that received A20^Hem-KO^ BM ([Fig. 7, L and M](#fig7){ref-type="fig"}). Overall, the data of the DKO mice suggested that the HSC phenotype of A20^Hem-KO^ mice was, at least in part, caused by elevated IFN-γ signaling.

![**Rescue of the HSC phenotype in A20^Hem-KO^ IFN-γ^−/−^ mice.** (A) Representative images of control, IFN-γ^−/−^, A20^Hem-KO^, and A20^Hem-KO^ IFN-γ^−/−^ (DKO) mice showing body size (*n* = 5). (B) Bar graphs showing body size of control (*n* = 9), A20^Hem-KO^ (*n* = 3), and DKO (*n* = 4) mice. (C) Kaplan-Meier survival curve analysis of control (*n* = 26), IFN-γ^−/−^ (*n* = 11), A20^Hem-KO^ (*n* = 10), and DKO (*n* = 15) mice. Significance (\*\*\*\*, P \< 0.0001) was assessed using the log-rank test. (D) FACS plots showing immunophenotype of LSK, LT-HSCs, ST-HSCs, and MPPs of 14-d-old control, IFN-γ^−/−^, A20^Hem-KO^, and DKO mice. Data are representative of two independent experiments. (E) Absolute numbers of LT-HSCs in the BM (two femurs and two tibias) of 14-d-old animals. Data are pooled from two independent experiments with two mice per group. (F) Frequencies of Sca1-expressing cells in the Lin^−^c-Kit^+^CD150^+^ fraction of the BM of 14-d-old animals. Data are pooled from two independent experiments with two mice per group. (G) Kaplan-Meier survival curve analysis of WT recipients after BMT. Data are pooled from two independent experiments with 11 mice each for control, A20^Hem-KO^, and DKO groups and 6 mice for the IFN-γ^−/−^ group. Significance (\*, P \< 0.03) was assessed using the log-rank test. (H) Frequencies of donor (CD45.2^+^) cells in the peripheral blood of WT congenic recipients at 5 wk after transplantation. Data are representative of two independent experiments and are pooled from six mice each for control and IFN-γ^−/−^ groups, five mice for the A20^Hem-KO^ group, and seven mice for the DKO group. (I) Frequencies of donor (CD45.2^+^) cells in the peripheral blood of WT congenic recipients at 14 wk after transplantation. Data are representative of two independent experiments and are pooled from five mice for control and four mice for DKO groups. (J and K) Frequencies of donor (CD45.2^+^) hematopoiesis in the peripheral blood of WT recipients, at 4 wk after transplantation. Recipients received mixed chimera containing donor (CD45.2^+^) BM cells (from A20^Hem-KO^, DKO, and control mice) and WT competitor (CD45.1^+^) BM cells at a ratio of 1:1 (J) and 5:1 (K), respectively. Data are representative of two independent experiments and are pooled from five mice each for A20^Hem-KO^ and DKO groups and four mice for control group (J) and five mice for DKO group, three mice for A20^Hem-KO^ group, and five mice for control group (K). (L and M) Frequencies of donor-derived cells in total CD11b^+^ (L) and CD19^+^ (M) fractions in the peripheral blood of WT recipients from the 1:1 group of J. Data are representative of two independent experiments and are pooled from five mice each for A20^Hem-KO^ and DKO groups and four mice for the control group. All data represent mean ± SEM. Two-tailed Student's *t* tests were used to assess statistical significance (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001).](JEM_20132544_Fig7){#fig7}

DISCUSSION
==========

In recent years, the ubiquitin-editing enzyme A20 has emerged as a central regulator of inflammation ([@bib20]). Germline deficiency of A20 in mice causes persistent activation of NF-κB, leading to multiorgan inflammation, cachexia, neonatal lethality, and increased responses to TNF and LPS ([@bib19]; [@bib3]). To understand the functions of A20 in the immune system, the *Tnfaip3* gene was deleted in selective immune compartments using tissue-specific Cre lines. Disrupting functions of A20 in B cells, using CD19 Cre, resulted in exaggerated NF-κB signaling and hyperresponsiveness to LPS/B cell receptor and CD40 ligation. In addition, A20 deficiency in B cells caused elevated levels of IL6 expression, spontaneous activation of B cells, expansion of myeloid cells, plasma cell hyperplasia, and autoimmunity at 3--4 mo of age ([@bib42]; [@bib6]). DC-specific deletion of A20, using CD11c Cre mice, resulted in spontaneous activation of DCs (which results in increased secretion of proinflammatory cytokines), B cells, T cells, and myeloid cells and development of lymphadenopathy and splenomegaly in 4--6-wk-old mice ([@bib11]; [@bib17]). Macrophage- and granulocyte-specific deletion of A20, using LysM Cre mice, caused spontaneous polyarthritis, increased systemic and local cytokine production, and increased osteoclast functions ([@bib22]). Although these studies have elegantly demonstrated the importance of A20-mediated NF-κB down-regulation in the immune system, almost all of these studies were focused on the role of A20 on the functions of immune cells. In the present study, we focused on the role of A20 in early hematopoiesis and found that A20 deficiency results in hyperproliferation of HSPCs and in premature depletion of the HSC pool. Thus, A20 acts as a key modulator in the maintenance of HSC quiescence, particularly under steady-state conditions.

The role of infection and inflammation in the control of hematopoiesis has gained a lot of attention in the recent years. Although it was believed that only lineage-committed progenitors, including CMP and CLP, were involved in sensing and in responding to infections ([@bib45]; [@bib2]), it is now evident that HSCs are directly involved in the primary response of both acute and chronic infections ([@bib15]). The direct response of HSCs to an immune insult might be a key determinant in the clearance of the pathogen because HSCs can dictate cell fate decisions and can preferentially differentiate into a particular hematopoietic lineage to clear the pathogen. HSCs have evolved to sense pathogens by both cell-intrinsic and -extrinsic mechanisms ([@bib2]; [@bib15]). HSPCs have been shown to recognize pathogens in a cell-intrinsic manner, through their expression of TLRs. In contrast, the cell-extrinsic mode of recognition of an immune insult by HSCs primarily involves expression and stimulation by proinflammatory cytokines and chemokines, which includes IL6, TNF, CC-chemokine ligand 2 (CCL2), IFN-α, and IFN-γ ([@bib2]; [@bib15]).

Indeed, long-term treatment of mice with low doses of LPS resulted in impaired self-renewal and multilineage differentiation of HSCs ([@bib8]). Exposure of HSCs to a combination of IL6, TNF, and CCL2, a condition which mimics LPS stimulation, resulted in defective long-term engraftment ([@bib4]).

Recent studies identified IFNs, both type I (IFN-α) and type II (IFN-γ), as major regulators of HSC quiescence. IFNs are produced by lymphocytes, such as NK cells, NKT cells, and T cells, during bacterial and viral infections. Although in vitro stimulation of HSCs with IFN-α has antiproliferative effects, in vivo treatment of mice with IFN-α results in loss of HSC quiescence, increased phosphorylation of STAT1 and AKT1, expression of IFN-α target genes, up-regulation of surface Sca1, and increased cell cycle activity mediated by Sca1 ([@bib9]). Interestingly, transient activation of HSCs by IFN-α did not affect the numbers of functional HSCs. However, long-term (chronic) activation of the IFN-α pathway in HSCs leads to decreased HSC activity and a marked competitive disadvantage in mixed BM reconstitution experiments ([@bib9]). Consistently, loss of IFN regulatory factor-2 (IRF-2), a transcriptional suppressor of IFN signaling, results in reduced HSC pool, diminished HSC quiescence, and compromised HSC functions as the result of increased IFN-α signals ([@bib38]). In contrast, stimulation of HSCs with IFN-γ leads to hyperproliferation of HSCs both in vitro and in vivo ([@bib1]), and IFN-γ has been shown to be sufficient to promote proliferation of long-term repopulating HSCs, accompanied by a remarkable increase of immediate downstream progenitors ([@bib1]). This study found a disadvantage in competitive repopulation assays after *Mycobacterium avium* infection (IFN-γ exposure) and proposed that baseline IFN-γ tone may influence HSC turnover and quality during normal homeostasis ([@bib1]). Consistently, [@bib16] showed that dysregulated IFN-γ signaling results in reduction of the HSC pool. Overall, our data agree with the existing paradigm of IFN signaling in HSCs ([@bib9]; [@bib16]; [@bib32]). The current study indicated that IFN-γ signaling has an indispensable role in the hematopoietic phenotype of A20-deficient mice. However, analysis of A20--IFN-γ DKO mice indicated only a partial rescue of the A20^Hem-KO^ phenotype. These data suggest that IFN-γ is one of the several factors contributing to the HSC phenotype of A20^Hem-KO^ mice. Other potential factors that could influence the phenotype of A20-deficient mice may include cytokines, such as type I IFNs, IL6, and TNF. Indeed, earlier studies identified critical roles of these cytokines in the control of HSCs and hematopoiesis ([@bib2]; [@bib15]; [@bib31]). Among these cytokines, it would be more interesting to study the role of type I IFNs, as mounting evidence documents the direct involvement of A20 in the negative regulation of two key inducers of type I IFN, IRF3 and IRF7 ([@bib14]; [@bib29]).

Further studies that aim to dissect the potential involvement of other proinflammatory cytokines in A20-deficient mice would be helpful in understanding the role of inflammation in HSC biology. We anticipate that our study contributes to a deeper understanding of hematological disorders in patients with *TNFAIP3* (*A20*) mutations.

MATERIALS AND METHODS
=====================

### Mice.

To generate *Tnfaip3* conditional KO mice, the mouse *Tnfaip3* exon 3 region and homology arms were PCR amplified from C57BL/6 mouse genomic DNA and cloned into the SalI, XhoI, and SfiI sites of the pEasy-FRTlox DT vector (provided by K. Rajewsky, Harvard Medical School, Boston, MA), which contains a neomycin resistance cassette for positive selection and a diphtheria toxin cassette for negative selection. The targeting vector was linearized by ClaI and electroporated into Bruce4 embryonic stem cells. G418-resistant clones were screened for homologous recombination by Southern blotting. Correctly targeted embryonic stem clones were injected into albino C57BL/6-cBrd/cBrd blastocysts (National Cancer Institute, Frederick, MD) and implanted into host female mice to generate chimeras. Chimeras were then bred to albino C57BL/6 mice to obtain black C57BL/6 litters, which were then screened for germline transmission of the allele. Mice were crossed to the ACTB-Flpe mouse strain (The Jackson Laboratory) to remove the neomycin cassette. VAV^Cre/+^, IFN-γ^−/−^, and IFN-γ reporter (GREAT) mice were purchased from The Jackson Laboratory. CD45.1 congenic animals were purchased from the National Cancer Institute. In our experiments, we used A20^+/+^, A20^F/+^, A20^F/F^, and A20^F/+^ Vav^Cre/+^ mice as controls, as none of these control animals exhibited any hematopoietic phenotype. However, in each experiment, age-and gender-matched littermates were used as controls. Mice were maintained under specific pathogen--free conditions and were used according to the protocols approved by the Institutional Animal Care and Use Committee of Columbia University Medical Center.

### Cell preparation.

A20^Hem-KO^ mice were analyzed at 14 d after birth (P14). RBCs were lysed with ammonium chloride (STEMCELL Technologies). Trypan blue (Amresco)--negative cells were counted as live cells.

### Flow cytometry.

Cells were analyzed by flow cytometry with either LSRFortessa or LSRII (both BD) and FACSDiva software (BD) or FlowJo software (Tree Star). Cell sorting was performed with a FACSAria (BD). The following monoclonal antibodies were used: anti-B220 (RA3-6B2), anti-CD19 (1D3), anti-CD3ε (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-CD34 (RAM34), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD48 (HM48-1), anti-CD117 (2B8), anti-Flt3 (A2F10.1), anti--Gr-1 (RB6-8C5), anti--Sca-1 (D7), and anti-Ter119 (TER119; from BD); anti-CD150 (TC15-12F12.2; from BioLegend); and anti-CD16/32 (93) and anti-CD127 (A7R34; from eBioscience). Cells incubated with biotinylated monoclonal antibodies were incubated with fluorochrome-conjugated streptavidin--peridinin chlorophyll protein--cyanine 5.5 (551419; BD) or streptavidin-allophycocyanin-Cy7 (554063; BD). In all of the FACS plots, the relative frequencies (%) of the gated fraction are indicated.

### BMT experiments.

For radioprotection assays, 10^6^ of BM cells were injected into lethally irradiated (10 Gy) congenic (CD45.1^+^) recipient mice. For competitive repopulation experiments, 4 × 10^5^, 1.2 × 10^6^, or 10^6^ of BM cells from either A20 control or A20^Hem-KO^ mice were mixed with 4 × 10^5^, 4 × 10^5^, or 2 × 10^5^ of WT (CD45.1^+^) BM cells (to obtain a ratio of 1:1, 3:1, or 5:1, respectively) and were injected into lethally irradiated congenic WT (CD45.1^+^) recipient mice. For serial transplantation, 6 × 10^5^ BM cells from the primary transplants were injected into lethally irradiated congenic WT recipients.

### Apoptosis assays.

Apoptotic cells were detected with the Annexin V PE Apoptosis Detection kit or Annexin V FITC Apoptosis Detection kit (BD) according to the manufacturer's instructions. For TUNNEL assay, the In Situ Cell Death Detection kit (Roche) was used according to the manufacturer's instructions.

### Cell proliferation experiments.

For BrdU assays, either 14-d-old (P14) mice or 1-d-old (P1) pups were injected i.p. with either 1 Mg or 200 µg BrdU (BD), respectively. At 16 h after injection, mice/pups were sacrificed and BM/liver cells were stained for BrdU, according to the BrdU Flow kit (BD) manufacturer's instructions, and detected by flow cytometry. For Ki-67 analysis, BM cells were stained for surface markers and fixed and permeabilized with FIX & PERM Cell Fixation & Cell Permeabilization kit (Life Technologies). These cells were further stained with anti--Ki-67 antibodies (B56; BD).

### SP assays.

BM cells were incubated with 5 µg/ml Hoechst 33342 (Life Technologies) at 37°C for 90 min.

### Cell cycle analysis.

For Pyronin Y analysis, cells were first incubated with 5 µg/ml Hoechst 33342 at 37°C for 45 min and then with 1 µg/ml Pyronin Y (Sigma-Aldrich) for an additional 45 min at 37°C. For cell cycle assays using Ki-67 and Hoechst, cells were stained with surface markers and fixed and permeabilized with Cytofix/Cytoperm fixation/permeabilization solution kit (BD). These cells were stained with Ki-67 for 30 min and subsequently stained with 20 µg/ml Hoechst 33342 for 5 min and analyzed by flow cytometry.

### Homing assay.

LSK cells were sorted from the BM and stained with CFSE (Life Technologies) for 15 min, and 5 × 10^4^ CFSE^+^LSK cells were injected i.v. into lethally irradiated (10 Gy) WT mice. 20 h after injection, mice were sacrificed, and CFSE-positive cells in the BM were analyzed by flow cytometry.

### Western blot analysis.

For immunoblot analyses, cells were lysed with cell lysis buffer (Cell Signaling Technology) with protease inhibitor cocktail (Complete; Roche) and 1 mM PMSF (Santa Cruz Biotechnology, Inc.). Cell lysates were boiled with sample buffer (NuPAGE; Life Technologies) containing 1% 2-Mercaptoethanol (Sigma-Aldrich). Proteins were subjected to 8--12% SDS-PAGE and transferred to PVDF membranes (Bio-Rad Laboratories). The membranes were blocked with either 5% bovine serum albumin (Life Technologies) or 5% skim milk and then treated with primary and secondary antibodies, respectively. The blots were visualized using the ProtoGlow ECL (National Diagnostics) and Image station 440 (Kodak). Antibodies used were as follows: anti-A20 (D13H3; Cell Signaling Technology), anti-IκBα (44D4; Cell Signaling Technology), anti--phospho-IκBα (5A5; Cell Signaling Technology), anti-actin (I-19; Santa Cruz Biotechnology, Inc.), HRP-conjugated anti--mouse and anti--rabbit IgG (Cell Signaling Technology), and HRP-conjugated anti--goat IgG (Santa Cruz Biotechnology, Inc.).

### IκBα degradation assay.

Splenocytes were stimulated with 1 µg/ml LPS (Sigma-Aldrich) at 37°C for 1 h, and then lysed for protein extraction. Cells with no stimulation served as controls.

### ChIP assay.

ChIP assay was performed with an Agarose ChIP kit (Thermo Fisher Scientific) according to the manufacturer's instructions. In brief, 10^7^ of BM cells were fixed and immunoprecipitated with either anti-p65 (D14E12; Cell Signaling Technology) or rabbit IgG (Thermo Fisher Scientific) antibodies. Immunoprecipitated DNA fragments were quantified by real-time PCR with the use of the following primers, which amplify the IFN-γ promoter region containing NF-κB--binding sites: forward, 5′-ACCCTGAGTGATTTGTAGTAGGT-3′; and reverse, 5′-GTGAATTTCTCATCCACAGAGCA-3′. Fold enrichment was normalized to rabbit IgG--precipitated samples.

### RNA extraction, PCR, and real-time PCR.

Total RNA was isolated with an RNeasy Mini kit (QIAGEN). cDNA was synthesized with Oligo(dT) primer and Maxima reverse transcription (Thermo Fisher Scientific). PCR was performed with T100 thermal cycler (Bio-Rad Laboratories) and TSG Taq (Lamda Biotech). Real-time PCR was performed in duplicates with a CFX-connect real-time PCR system (Bio-Rad Laboratories) and SsoAdvanced SYBR Green Supermix (Bio-Rad Laboratories) according to the manufacturer's instructions. Relative expression was normalized to the expression levels of the internal control (housekeeping gene) *Hprt*.

### Statistical analyses.

We used the unpaired Student's *t* test for all the experiments, except survival experiments. For survival curve analysis, log-rank test was used. Differences with P \< 0.05 were considered statistically significant and are denoted as \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.
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